Department of Chemistry and Biochemistry Mendel University in Brno, Zemedelska 1, 613 00 Brno, Czech Republic.
Central European Institute of Technology, Brno University of Technology, Purkynova 656/123, 612 00 Brno, Czech Republic.
Theranostics. 2021 Jan 1;11(4):1546-1567. doi: 10.7150/thno.48662. eCollection 2021.
Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials. Some nanocarrier properties provide improvement of drug efficacy, reduce the incidence of adverse events, enhance drug bioavailability, helps to overcome the blood-brain barrier, increase drug stability or allow for specific delivery of TKIs to the diseased cells. Moreover, nanotechnology can bring new perspectives into combination therapy, which can be highly efficient in connection with TKIs. Lastly, nanotechnology in combination with TKIs can be utilized in the field of theranostics, i.e for simultaneous therapeutic and diagnostic purposes. The review provides a comprehensive overview of advantages and future prospects of conjunction of nanotransporters with TKIs as a highly promising approach to anticancer therapy.
纳米医学和靶向治疗的最新进展为酪氨酸激酶抑制剂（TKIs）的治疗应用领域带来了新的机遇。由于这些药物的作用机制是非靶向的，会产生许多副作用，从而影响患者的生活质量，或者导致药物在临床试验中失败。一些纳米载体的特性可以提高药物的疗效，降低不良反应的发生率，提高药物的生物利用度，有助于克服血脑屏障，增加药物的稳定性，或者使 TKI 能够特异性地递送到病变细胞。此外，纳米技术可以为联合治疗带来新的视角，与 TKI 联合使用可能非常有效。最后，纳米技术与 TKI 结合可以应用于治疗诊断学领域，即同时具有治疗和诊断目的。本文综述了纳米转运体与 TKI 结合作为一种很有前途的抗癌治疗方法的优势和未来前景。
